SGMO vs. BLUE, CLLS, ATRA, ADAP, LXRX, VNDA, XOMA, AGEN, EBS, and CDXS
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include bluebird bio (BLUE), Cellectis (CLLS), Atara Biotherapeutics (ATRA), Adaptimmune Therapeutics (ADAP), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Agenus (AGEN), Emergent BioSolutions (EBS), and Codexis (CDXS). These companies are all part of the "medical" sector.
bluebird bio (NASDAQ:BLUE) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.
bluebird bio currently has a consensus target price of $5.46, suggesting a potential upside of 504.66%. Sangamo Therapeutics has a consensus target price of $5.67, suggesting a potential upside of 904.02%. Given bluebird bio's stronger consensus rating and higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than bluebird bio.
bluebird bio has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.
bluebird bio received 596 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics has higher revenue and earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
bluebird bio has a net margin of -419.64% compared to bluebird bio's net margin of -1,749.06%. Sangamo Therapeutics' return on equity of -34.32% beat bluebird bio's return on equity.
87.4% of bluebird bio shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 2.1% of bluebird bio shares are owned by insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, bluebird bio had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 6 mentions for bluebird bio and 3 mentions for Sangamo Therapeutics. bluebird bio's average media sentiment score of 1.09 beat Sangamo Therapeutics' score of 0.61 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.
Summary
bluebird bio beats Sangamo Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
